# DUMAS: HCP commentary report

> 17 verified statements (3 from clinicians verified by NPI or staff page) from 8 commentary sources · 5 findings · updated Oct 30, 2026

## Report

- Trial: Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study
- NCT ID: NCT05684276
- Registry: https://clinicaltrials.gov/study/NCT05684276
- Sponsor: Fundación GECP
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: nivolumab plus carboplatin plus paclitaxel
- Indication: NSCLC with Pancoast tumor
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: 08ac526ccaf7df0e461e4843a3563d0846bcd946d6ceb5acfca74f2d9e7a8422

## Counts

- HCP commentary sources screened: 49
- Sources cited by verified statements: 9
- Verified statements: 17
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 3
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Voices cited: 5
- Cited voices identity-verified: 3
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on DUMAS in the sources reviewed for this edition leads to one open question: What additional survival maturity, comparative evidence and surgical expertise would justify a defined change in Pancoast care? Its leading findings: (1) clinical implications are asserted alongside a request for more mature survival. (2) response denominators and differing survival summaries limit a single numerical reading. (3) the treatment-change question is qualified by surgical expertise. 2 more findings follow. 49 sources screened, 9 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What additional survival maturity, comparative evidence and surgical expertise would justify a defined change in Pancoast care?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Clinical implications are asserted alongside a request for more mature survival
- F2. Response denominators and differing survival summaries limit a single numerical reading
- F3. The treatment-change question is qualified by surgical expertise
- F4. Prospective evidence is valued against a difficult comparative-evidence backdrop
- F5. A supportive reply celebrates Spanish research rather than a treatment decision

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 6 | 4 | 4 | 4 | none recorded | 3 |
| F2 | 3 | 3 | 3 | 3 | none recorded | 3 |
| F3 | 5 | 3 | 3 | 3 | none recorded | 2 |
| F4 | 4 | 4 | 4 | 3 | none recorded | 2 |
| F5 | 1 | 2 | 1 | 1 | none recorded | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 5 | 0 | 0 | 0 | 1 | 7 | 1 | 4 posts and articles | yes |
| F2 | 1 | 0 | 0 | 0 | 2 | 3 | 1 | 3 posts and articles | yes |
| F3 | 4 | 1 | 0 | 0 | 0 | 6 | 0 | 3 posts and articles | yes |
| F4 | 2 | 0 | 0 | 0 | 2 | 4 | 1 | 4 posts and articles | yes |
| F5 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 post or article | no |

### Trial dimensions

- Primary endpoint: Estimate progression-free survival (PFS): F1 (3 shared claims), F2 (3 shared claims), F3 (1 shared claims)
- Secondary endpoint: Overall survival: F2 (1 shared claims)
- Secondary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability): no finding draws on it directly
- Secondary endpoint: Complete resection (R0) rate: F2 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims)
- The comparison: F1 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F1 (1 shared claims), F4 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 17 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 9 | Counts free |
| Speaker attribution for cited voices | 5 | Paid |

## Trial aspects

11 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Estimate progression-free survival (PFS) | discussed | 5 | 3 |
| Secondary endpoint: Overall survival | discussed | 1 | 1 |
| Secondary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | no commentary found | 0 | 0 |
| Secondary endpoint: Complete resection (R0) rate | discussed | 1 | 1 |
| Population and setting | discussed | 4 | 4 |
| The comparison | discussed | 1 | 1 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 3 | 3 |
| Pathological response and surgical uptake | discussed | 5 | 5 |
| Clinical implications and readiness to change care | discussed | 4 | 4 |
| Surgical expertise and routine-care translation | discussed | 2 | 2 |
| Evidence generation and comparative-study feasibility | discussed | 3 | 3 |
| Pride in Spanish research | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 31 | 8 |
| Bluesky threads | 10 | 0 |
| Podcasts | 6 | 0 |
| YouTube | 2 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-03-20 to 2026-10-16
- Cited window: 2025-02-03 to 2026-09-15
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study
- Registry: NCT05684276 (https://clinicaltrials.gov/study/NCT05684276)
- Study IDs: GECP 22/02_DUMAS · 2022-003717-11
- Sponsor: Fundación GECP
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Active, not recruiting
- Enrollment: 22 (estimated)
- Start: 2023-05-12 (actual)
- Primary completion: 2028-03-01 (estimated)
- Primary endpoint: Estimate progression-free survival (PFS) (From the date randomization until the date of last follow up, assessed up to 24 months)
- Intervention: Carboplatin (drug)
- Intervention: Paclitaxel (drug)
- Intervention: Nivolumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- Coverage is limited to the sources reviewed for this edition. Discussion that does not explicitly name the trial may be missing, and some available passages were not fully evaluated.
- No original DUMAS results publication was identified for this edition, and the registry did not list a separate protocol document. Numerical outcomes are discussed through social-media summaries.
- The sources do not explain the different reported PFS figures, and some response and survival percentages lack a denominator, endpoint subtype or timepoint.
- The reviewed statements provide no adverse-event or tolerability assessment; favorable response and survival reactions do not establish a favorable safety profile.
- The separate Pancoast case cohort and SWOG comparison provide treatment-choice context, not DUMAS outcomes.
- Some authors' clinical roles are not established. Organizational coverage, presentation relays and reposts cannot be treated as independent HCP opinions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition

Last checked for new commentary 2026-10-30. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (17 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (3 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/dumas-nct05684276
- Agents: POST https://www.erudio.com/api/orders with {"report": "dumas-nct05684276", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=dumas-05684276

## Cite

Erudio Health. DUMAS (NCT05684276): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/dumas-nct05684276

## Machine access

- JSON: https://www.erudio.com/reports/dumas-nct05684276.json
- Markdown: https://www.erudio.com/reports/dumas-nct05684276.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "dumas-05684276"}`